Sionna Therapeutics halts genetic-disorder drug after mid-stage trial failure
Sionna Therapeutics said it will halt development of its experimental drug as an add-on to standard therapy for a genetic disorder after a mid-stage trial failed to demonstrate meaningful benefit. The move eliminates a potential growth driver and could pressure shares in the near term while management reevaluates the pipeline and reallocates resources to other programs or partnerships.
View signal analysis